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Abstract Gelonin (a toxin and type II ribosome inactivating 
protein) when linked to human transferrin can be targeted to 
Plasmodium falciparum. The transferrin toxin conjugate is 
significantly toxic to parasite growth and is 25 times more 
potent than toxin alone in inhibiting parasite protein synthesis. 
The mechanism of its entry into the intraerythrocytic parasite is 
discussed. 
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1. Introduction 
Plasmodium falciparum malaria is responsible for the mor- 
),idity and mortality of several million children under the age 
, ,f 5, in Asia and Africa alone. The rapid and unprecedented 
~Lse of multidrug resistance and the recent pessimism about 
~iae prospects of a malaria vaccine make new therapeutic ap- 
?roaches of paramount significance [1]. Antigens ynthesized 
!,y plasmodial trophozoites and schizonts, present on the sur- 
face of IRBCs of the host, can be envisaged for targeting 
~. hemotherapeutic agents to the intracellular parasites [2]. 
RIPs are a family of toxins, produced by plants, that in- 
~ ctivate eukaryotic ribosomes [3]. These toxins have catalytic 
properties and only a small number of molecules need to 
J each cytosol to inactivate ribosomes to kill the cells. These 
oxins can be divided into two groups, those composed of two 
• ubunits, termed type I RIPs (viz. ricin) and those having only 
l he toxic chain, termed type II RIPs (viz. gelonin). Ricin, ricin 
\ chain and gelonin upon internalization irreversibly inacti- 
ate the protein synthesis through their A chains, by release of 
: single adenine 4324 from the 28S rRNA found in the 60S 
ubunit  of eukaryotic ribosomes leading to cell death [4]. 
?ransferrin is the donor of non-heme iron (Fe3+), essential 
or  the survival of the malaria parasite [5 7]. Internalization 
,f transferrin by a mechanism reminiscent of receptor 
nediated endocytosis indicates the existence of its receptor 
,n the surface of IRBCs [8,9]. The intracellular parasites 
ynthesize and translocate this receptor to the membrane of 
mature erythrocytes, which are otherwise devoid of it. The 
~arasite transferrin receptor, unlike its human counterpart is 
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tbbreviations. IRBC, infected red blood cells; URBC, uninfected red 
~lood cells; RIP, ribosome inactivating protein; SMCC, N-succinimi- 
,lyl-4-(N-maleimidomethyl)cyclohexane-l-carboxylate; EMEM, Ea- 
,'le's minimal essential medium; Tf, transferrin; [125I]Tf[Fe2+], 
~odinated holotransferrin; PBS, phosphate buffered saline; SDS- 
!)AGE, sodium dodecyl sulfate-polyacrylamide gel lectrophoresis 
not a disulfide linked dimer of subunits of M~ 95 000 each, but 
is made of single polypeptide of Mr 102000 [10]. Data ques- 
tioning the existence of this receptor as well as its involvement 
in iron transport have also been reported [11]. 
That targeted toxins represent a rational approach to cyto- 
cidal therapy in certain infectious diseases, envisaged earlier, 
has indeed been attested to, by the success of anti CD4-toxin 
and CD4-toxin conjugates for combating human immunode- 
ficiency virus [12,13]. Moreover, such hybrid molecules pre- 
pared by chemical conjugation, linked to either antireceptor 
antibodies or ligands, have been demonstrated to selectively 
kill cells, displaying the complementary determinants (antigen 
or receptor) on their surfaces [14]. 
In this report we present evidence that this approach can be 
used for directed cytotoxicity towards the malaria parasite. 
When conjugate of human sero-transferrin to gelonin (or ricin 
A chain) is used, it selectively binds to IRBCs, by virtue of the 
presence of transferrin receptors on their cell surface, followed 
by the release of the toxic subunit into the cytosol of the 
parasite, leading to inhibition of parasite protein synthesis 
and eventual death. 
2. Materials and methods 
2.1. Materia& 
Human sero-transferrin, Vibrio cholerae neuraminidase, iminothio- 
lane and anti-transferrin a tibodies were from Sigma, St. Louis, MO, 
USA. Sephadex G-25 and Sephadex G-100 were the products of Phar- 
macia, Iodobeads and N-succinimidyl-4-(N-maleimidomethyl) cyclo- 
hexane-l-carboxylate (SMCC) were obtained from Pierce. Carrier- 
free Na[12~I] (200 Ci/mmol) was obtained from Bhabha Atomic Re- 
search Centre, Bombay, India. [35S]Methionine (800 Ci/mmol) was 
from Amersham. The anti-gelonin antibody Sepharose was available 
from a previous tudy [15]. 
2.2. Maintenance of parasite culture and synchronization of different 
stages of parasite 
P. falciparum FCK2 strain was maintained as described in [16] 
using the method of Trager [17]. Parasites (8-10% parasitemia) were 
synchronized using 5% D-sorbitol [18]. Trophozoite stage was used for 
most of the experiments unless otherwise stated. 
2.3. Parasite protein synthesis and growth inhibition assays 
Cell-free parasite protein synthesizing system was prepared as de- 
scribed by Surolia and Padmanaban [16]. Effects of various toxins and 
their conjugates on parasite growth were measured by microscopic 
examination of thin smears tained with Giemsa stain as well as by 
monitoring short-term [aSS]methionine incorporation by parasites into 
the trichloroacetic acid precipitable fraction after toxin/conjugate 
treatment [19]. Cell viability was also monitored by counting the in- 
fected cells and by the trypan blue exclusion method. 
2.4. Preparation of ricin, ricin A chain and gehmin 
Ricinus agglutinin (RCA I) and ricin were purified according to [20]. 
Ricin was separated from agglutinin by gel filtration on Sephadex 
G-100 as described in [21]. Ricin A and its B chains were prepared 
according to the method of Shimizu et al. [22]. Gelonin was purified 
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according to [3]. Activities of ricin, ricin A chain and gelonin were 
assayed as described in [3] using a rabbit reticulocyte lysate system 
prepared according to Jagus [23]. 
2.5. Preparation of gelonin-transferr& conjugate 
Gelonin-transferrin conjugate was prepared as described in [24]. 
Transferrin (10 mg) in 0.1 M sodium phosphate buffer (pH 7.4) was 
treated with a 25-fold molar excess of SMCC for 1 h at 25°C. Sub- 
sequent to the removal of excess SMCC by gel filtration on Sephadex 
G-25 (1 x25 cm), 1.8 2.1 molecules of SMCC were incorporated per 
molecule of transferrin. Gelonin (25 mg) was thiolated with a 25-fold 
molar excess of 2-iminothiolane according to [25] under nitrogen at- 
mosphere at 25°C. This led to the incorporation of 0.9-1.1 sulfhydryl 
groups per gelonin molecule. The conjugate was then prepared by 
incubating a 5-fold molar excess of derivatized gelonin over SMCC- 
transferrin for 24 h at 4°C in 0.1 M sodium phosphate buffer pH 7.4, 
under nitrogen atmosphere. The remaining maleimido groups were 
saturated with 1.5 mM 2-mercaptoethanol. Gelonin-transferrin con- 
jugate was separated from free gelonin and transferrin by gel filtration 
on a superfine Sephadex G-100 column ( lAx  100 cm), equilibrated 
and eluted with 0.1 M sodium phosphate buffer (pH 7.4). Ricin A and 
B chain-transferrin conjugates were also prepared and characterized 
as above except hat the thiolation step was omitted, as both of these 
chains contain sulfhydryl groups [26]. 
2.6. Binding studies 
Transferrin was saturated (-> 95%) with iron according to the meth- 
od of Larrick and Cresswell [27]. Transferrin and gelonin-transferrin 
conjugates were iodinated by the chloramine T method [28] and sep- 
arated from free [125I] by gel filtration on Sephadex G-25. IRBCs 
were incubated with EMEM with Earle's salts for 20 min to ensure 
that the receptor-bound transferrin was dissociated. To measure bind- 
ing, defined concentrations of iodinated holotransferrin [125I]TI~Fe2+] 
(4.2 x 105 cpm/lag protein, prepared in our laboratory) or iodinated 
gelonin-transferrin(Fe 2+) conjugate (1.1 × 106 cprn/~tg protein), were 
added to IRBCs and URBCs in a final volume of 0.2 ml EMEM 
containing 4 mg/ml bovine serum albumin for 20 rain at 15°C. Sub- 
sequently, the cells were washed four times with 1 ml chilled PBS and 
the cell-associated radioactivity quantified in a gamma counter. The 
binding data were analyzed according to Steck and Wallach [29]. 
3. Results 
3.1. Immunoprecipitation f the parasite transferrin receptor by 
anti-transferrin antibody 
A monospecific antibody purified from polyclonal sera 
raised against IRBCs in rabbit immunoprecipitated a 100 
kDa band in IRBCs but not in URBCs. Conjugate of gelonin 
with this antibody was found to be a more potent cytotoxic 
agent than gelonin to the malaria parasite [30]. Detailed ex- 
amination of the antigen on the IRBCs revealed it to be the 
transferrin receptor. 
3.2. Characterization of gelonin-transferrin conjugate 
The conjugate was separated from free transferrin and ge- 
lonin by gel filtration on a Sephadex G-100 column (Fig. 1). 
On rechromatography of the conjugate (peak I), peaks lI and 
III did not reappear. SDS-PAGE of the conjugate showed a 
single band with Mr 110 000 which corresponds to the molec- 
ular masses of the hybrid of transferrin and gelonin with a 
stoichiometry close to 1:1 (data not shown). As transferrin 
contains the biantennary N-linked oligosaccharide chain 
which on treatment with neuraminidase exposes its terminal 
13-galactosyl residues, affinity chromatography of an aliquot 
(1 rag) of the conjugate on a RCA I-Sepharose (1x5  cm; 
10 mg RCA Ilml gel) column was carried out to evaluate 
the presence of free gelonin in the preparation [31,32]. All 
of the desialylated conjugate was retained on the RCA I- 
Sepharose column and no free gelonin was observed in the 
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Fig. 1. Gel filtration of transferrin-gelonin conjugate on Sephadex 
G-100. Subsequent to the coupling step of conjugation the reaction 
mixture was loaded on the column equilibrated and eluted with 0.1 
M phosphate buffer, pH 7.4. Peak I, II and III indicate peaks for 
conjugate, transferrin and gelonin respectively. Peak I was pooled at 
positions indicated by slashes in the figure. 
washes. Likewise no free transferrin was detected in the 
washes when 500 /ag of the conjugate was loaded on anti- 
gelonin-Sepharose column (1 X 5 cm; 8 mg antibody/ml gel). 
Based on these results, it is concluded that the conjugate thus 
prepared is devoid of free gelonin or transferrin. Under reduc- 
ing conditions, two protein peaks, II and III, corresponding to 
transferrin and gelonin respectively, were obtained on the 
above column. Based on the protein content of each peak 
the molar ratio of transferrin and gelonin in the conjugate 
was found to be close to 1:1.05. 
3.3. Characterization of transferrin receptor sites on 1RBCs 
[125I]Transferrin fails to bind to URBCs even at concentra- 
tions where its binding to IRBCs is saturated. The quantity of 
[a25I]transferrin bound to synchronized IRBCs is shown in 
Fig. 2A. These binding data were utilized to calculate the 
number of transferrin receptor sites and their association con- 
stants according to [29]. About 97 000 (+ 15 000) transferrin 
receptors were found per IRBC with an association constant 
of 5 x 106 M -1. Gelonin-transferrin or ricin-transferrin conju- 
gates also bound to IRBCs but not to URBCs. Moreover, the 
number of binding sites and their affinities for binding to the 
IRBCs were identical to those observed for transferrin itself, 
indicating that these hybrids bind to the same receptor. 
3.4. Inhibition of cell-free parasite protein synthesis by gelonin, 
ricin A chain and gelonin-transferrin conjugate 
As shown in Fig. 3 gelonin and ricin A chain, at 10-12 
ng/ml, inhibited the parasite protein synthesis by 50% within 
10 rain of incubation with the lysate, which corresponds to the 
linear region of parasite protein synthesis [16]. Parasite pro- 
tein synthesis virtually ceases (~ 80%) at 40-45 ng/ml of these 
toxins. Since both gelonin and ricin A chain were found to be 
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tig. 2. Quantification of transferrin receptor sites on IRBCs. A: [125I]Fe2+-Transferrin (I) or [12~I]conjugate of Fe+2-transferrin with gelonin 
(O) was incubated for 20 rain at 15°C with synchronized cultures (8% parasitemia, trophozoite stage) in EMEM. Subsequently the cells were 
x~ ashed 4 times with chilled PBS and the cell associated radioactivity counted on a gamma counter. URBCs were treated in an identical manner 
~, nd were used as controls. B: Scatchard analysis of data in A. 
equally effective in inhibiting protein synthesis, gelonin was 
tsed for most of the studies unless otherwise stated. The ge- 
])nin-transferrin conjugate at 150 ng/ml inhibited protein 
synthesis up to 82%. Thus the toxicity of the conjugate is 
tmilar to that of gelonin alone, in molar terms. 
. 5. Effect of gelonin and gelonin-transferrin conjugate on 
parasite growth and viability 
The toxic effect of gelonin on the growth of the malaria 
1,arasite is observed at micromolar concentrations (Fig. 4). 
Thus, 1 ~tM gelonin inhibits parasite growth by 50%, while 
5 pM is inhibitory up to 90%. Ricin A chain and ricin were 
equally potent in inhibiting the parasite growth (data not 
shown). These toxins are relatively less toxic to the intracel- 
lular parasites as compared to eukaryotic ells [3,26]. Gelonin- 
transferrin conjugate was 20-25 times more toxic to cells than 
gelonin alone. Incubation of cultures (8% parasitemia, tropho- 
zoite stage) with 50-100 nM conjugate led to 50% and 95°/,, 
inhibition of parasite growth respectively as monitored by 
[35S]methionine uptake, microscopic examination of the 
"ab le  1 
} ffect of conjugates in combination with antibodies or NH4C1 on P. falciparum growth 
~ lonjugate Addition Cell growth (%) 
ielonin-transferrin (50nM) 




Ricin A chain-transferrin (50 nM) 
l'icin A chain-transferrin (50 nM) 
Ricin B chain-transferrin (100 nM) 
- 43 
93 
Anti-gelonin antibody (10 I.tM) 90 
Anti-transferrin a tibody (10 ~tM) 94 
NH4CI (2 mM) 45 
NH4CI (2 mM) 90 
53 
Ricin B chain-transferrin (100 nM) 51 
- 97  
Cultures in microtiter plates (8% parasitemia, trophozoites) were incubated with conjugates or conjugates in combination with other compounds 
4coincubation) as described for Fig. 4. Incubation with NH4CI was for 24 h prior to [aSS]methionine addition. Details of incubation with 
[~S]methionine and measurement of radioactivity are given in the legend to Fig. 4. Samples were analyzed in triplicate. 
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smears and the trypan blue exclusion method. Results ob- 
tained by microscopic examination of parasites and [3~S]me- 
thionine incorporation were quantitatively similar. Micros- 
copy makes it possible to score the parasite number and 
morphology, whereas [35S]methionine uptake measures the 
parasite's ability to synthesize protein, utilizing a precursor. 
By 72 h after toxin treatment schizonts are seen to degenerate 
completely (Fig. 5). Coincubation of the conjugate with anti- 
gelonin antibodies (10 pM) or anti-transferrin a tibodies (10 
p.M) blocked the toxicity (Table 1). It may be noted that 
coincubation of ricin A chain-transferrin (50 nM) and ricin 
B chain-transferrin (I00 nM) conjugates does not have any 
effect over and above that observed for ricin A chain-trans- 
ferrin alone (Table 1) [33]. Likewise the addition of 2 mM 
NH4C1 does not enhance the toxicity of the gelonin-transfer- 
rin conjugate. 
4.  D iscuss ion  
These studies were undertaken to confirm the presence of 
transferrin receptors on IRBCs and to examine the feasibility 
of targeting toxin-transferrin conjugate to the intracellular 
malaria parasite as an alternative chemotherapeutic approach. 
Our studies clearly establish that the concentration dependent 
and saturable binding of transferrin and gelonin-transferrin 
conjugate to IRBCs is due to transferrin-receptors n these 
cells. Transferrin, gelonin-transferrin conjugate and gelonin 
by itself are unable to bind to URBCs, whereas gelonin did 
not bind to infected erythrocytes. 
Unlike eukaryotes, prokaryotes are completely resistant to 
these toxins. Malaria parasites, as shown here, are susceptible 
to their cytotoxic effects. In this respect he plasmodial ribo- 
somes differ from those of another protozoan, Tetrahymena 
pyriformis, which is totally resistant to these toxins [34]. An 
analysis of the structures of rRNAs of P. falciparum and T. 
pyriformis hould reveal the basis for differences in their sus- 
ceptibilities towards these RIPs. In accordance with these re- 
sults, these proteins (ricin, ricin A chain, gelonin and gelonin- 
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Fig. 3. Effect of toxins on in vitro protein-synthesizing system of P. 
falciparum. The assay was initiated by the addition of 
[3~S]methionine to the S-30 preparations [18] with or without (con- 
trol) the toxin and terminated after 10 min. The [35S]methionine i - 
corporation was measured by spotting an aliquot on filter disks fol- 
lowed by washing with hot trichloroacetic a id-H~O2, alcohol:ether 
and ether. Gelonin (3, ricin A. Ricin A chain showed activity simi- 
lar to ricin. 
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Fig. 4. Dose-response of gelonin and gelonin-transferrin conjugate 
on P. falciparum growth. P. falciparum growth was monitored by 
[35S]methionine i corporation i to parasite proteins as mentioned in
the text. Cultures (8% parasitemia, trophozoites) were incubated 
with the toxin or its conjugate at 37°C for 15 min, in incomplete 
RPMI 1640 medium, which was then replaced with complete 
RPMI. Cultures were further incubated at 37°C. The medium was 
changed every 24 h. To monitor parasite growth, smears as well as 
[asS] incorporation i to the trichloroacetic a id-precipitabe fraction 
was monitored at 24 h, 48 h and 72 h. At these time points, the 
parasite pellet was lysed and an aliquot used for measurement of 
radioactivity on filter disk as described in Fig. 3. [35S]Methionine 
was added 2 h prior to monitoring the incorporation, i.e. at 22 h, 
44 h and 70 h. Trypan blue exclusion assays were also carried out 
at these time points. Gelonin (A) and conjugate ((3) treated, after 
72 h. 
this parasite and inhibit cell-free parasite protein synthesis 
significantly. A finding of considerable interest is the stage 
specific effects of the toxin and its transferrin conjugate on 
Plasmodium growth. The conjugate-treated parasites do not 
infect fresh erythrocytes atall, as the parasite growth is totally 
arrested at the schizont stage, which are completely degener- 
ated and are seen as debris outside the cells (Fig. 4). In this 
respect he effect of the conjugate is schizontocidal, like an- 
other antimalarial agent, chloroquine, though the mode of 
action may be different. 
In contrast o its highly cytotoxic effect on many cell lines 
and eukaryotic ells, ricin was much less toxic to parasites 
compared to gelonin or ricin A chain, which is probably 
due to its poor endocytosis. Moreover, the uptake of the 
conjugate does not appear to follow the conventional route 
of receptor-mediated endocytosis and processing in an acidic 
compartment, as the addition of a high concentration f the 
lysosomotropic amine NH4C1, along with the conjugate does 
not potentiate the cytotoxic effect of the conjugate (Table 1) 
[35]. 
lmmunotoxins (conjugate of toxins and their antibodies) 
made up of type II RIPs are much less toxic than those 
made up of type I RIPs. Coincubation of the A chain con- 
jugate with B chain conjugate nhances cytotoxicity of the 
former, which is explained by assuming that such conjugates 
are endocytosed independently and recombine in an intracel- 
lular compartment, where the B chain promotes the entry of 
the A chain to the cytosol, enhancing its cytotoxicity. In our 
studies, the absence of a stimulatory effect of the B chain 
conjugate on the A chain conjugate further proves that these 
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l'ig. 5. Effect of transferrin-gelonin conjugate on parasite morphol- 
gy. The conjugate (100 nM) was incubated with cultures (8% para- 
• itemia, trophozoites) as described in legend for Fig. 3. Giemsa- 
tained smears were examined after 72 h. A: Control (without con- 
Jgate) after 72 h; B: conjugate treated, after 72 h. 
i~ybrids are not being endocytosed in this parasite, as in other 
ukaryotes [33]. That transferrin-ricin conjugate was as toxic 
,.s its A chain counterpart or gelonin-transferrin conjugate 
~nd the non-toxicity of transferrin-ricin B chain conjugate 
~urther corroborate these observations. 
Given such a scenario, what could be the mechanism for the 
,nhanced cytotoxicity of the conjugate. Questions regarding 
he accessibility and uptake of macromolecules and nutrients 
n malaria parasite have been a subject of intense investiga- 
ions. Two divergent views about the uptake are direct access 
o the parasite plasma membrane by parasitophorous duct 
36] in the IRBC throughout the life cycle of the parasite in 
he erythrocytes and a phospholipid/lipid recruitment pathway 
37]. Irrespective of its mechanism of entry, the toxin-trans- 
errin conjugate is shown here to be a potent cytotoxic agent 
md its targeted elivery and alternative approach for chem- 
otherapy to malaria parasite. 
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